WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573764
Description: AM-3102 is an OEA analog that stimulates PPARα transcriptional activity and prolongs feeding latency. It is resistant to enzymatic hydrolysis and is as potent as OEA in enhancing transcriptional activity of PPARα and reducing food intake in free-feeding rats. AM3102 demonstrates weak affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors.
MedKoo Cat#: 573764
Chemical Formula: C21H41NO2
Exact Mass: 339.3137
Molecular Weight: 339.56
Elemental Analysis: C, 74.28; H, 12.17; N, 4.12; O, 9.42
Synonym: AM-3102, AM3102, AM 3102, KDS-5104, Methyl oleoylethanolamide
IUPAC/Chemical Name: 9-Octadecenamide, N-((1R)-2-hydroxy-1-methylethyl)-, (9Z)-
InChi Key: IPVYNYWIRWMRHH-JPMGXVIASA-N
InChi Code: 1S/C21H41NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21(24)22-20(2)19-23/h10-11,20,23H,3-9,12-19H2,1-2H3,(H,22,24)/b11-10-/t20-/m1/s1
SMILES Code: CCCCCCCC\C=C/CCCCCCCC(=O)N[C@H](C)CO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 339.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Orio L, Alen F, Pavón FJ, Serrano A, García-Bueno B. Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse. Front Mol Neurosci. 2019 Jan 9;11:490. doi: 10.3389/fnmol.2018.00490. eCollection 2018. Review. PubMed PMID: 30687006; PubMed Central PMCID: PMC6333756.
2: Bowen KJ, Kris-Etherton PM, Shearer GC, West SG, Reddivari L, Jones PJH. Oleic acid-derived oleoylethanolamide: A nutritional science perspective. Prog Lipid Res. 2017 Jul;67:1-15. doi: 10.1016/j.plipres.2017.04.001. Epub 2017 Apr 5. Review. PubMed PMID: 28389247.
3: Brown JD, Karimian Azari E, Ayala JE. Oleoylethanolamide: A fat ally in the fight against obesity. Physiol Behav. 2017 Jul 1;176:50-58. doi: 10.1016/j.physbeh.2017.02.034. Epub 2017 Feb 27. Review. PubMed PMID: 28254531.
4: Zhou H, Yang WS, Li Y, Ren T, Peng L, Guo H, Liu JF, Zhou Y, Zhao Y, Yang LC, Jin X. Oleoylethanolamide attenuates apoptosis by inhibiting the TLR4/NF-κB and ERK1/2 signaling pathways in mice with acute ischemic stroke. Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):77-84. doi: 10.1007/s00210-016-1309-4. Epub 2016 Oct 13. PubMed PMID: 27738712.